Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Goel NJ, Bird CE, Hicks WH, Abdullah KG. Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment. J Med Econ 2021;24:1018-1024. [PMID: 34353213 DOI: 10.1080/13696998.2021.1964775] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]

For:	Goel NJ, Bird CE, Hicks WH, Abdullah KG. Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment. J Med Econ 2021;24:1018-1024. [PMID: 34353213 DOI: 10.1080/13696998.2021.1964775] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]

Number

Cited by Other Article(s)

Woo PYM, Pu JKS, Li LF, Wong DKK, Hui VKH, Chan DTM, Lee MWY, Chan TKT, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, Ko NMW, Loong HHF, El-Helali A, Lam TC, Cheung FC, Poon WS. Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study. J Neurooncol 2025;173:317-330. [PMID: 40067514 DOI: 10.1007/s11060-025-04985-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2024] [Accepted: 02/22/2025] [Indexed: 05/27/2025]

Affiliation(s)

Peter Y M Woo Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong.
Jenny K S Pu Department of Neurosurgery, Queen Mary Hospital, Hong Kong Island, Hong Kong
Lai-Fung Li Department of Neurosurgery, Queen Mary Hospital, Hong Kong Island, Hong Kong
Desiree K K Wong Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong
Victor K H Hui Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong
Danny T M Chan Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong
Michael W Y Lee Department of Neurosurgery, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
Tony K T Chan Department of Neurosurgery, Princess Margaret Hospital, Kwai Chung, Hong Kong
Jason M K Ho Department of Neurosurgery, Tuen Mun Hospital, Tuen Mun, Hong Kong
Ka-Man Cheung Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
Teresa P K Tse Department of Neurosurgery, Princess Margaret Hospital, Kwai Chung, Hong Kong
Sarah S N Lau Department of Neurosurgery, Queen Mary Hospital, Hong Kong Island, Hong Kong
Joyce S W Chow Department of Neurosurgery, Queen Elizabeth Hospital, Kowloon, Hong Kong
Natalie M W Ko Department of Neurosurgery, Kwong Wah Hospital, Kowloon, Hong Kong
Herbert H F Loong Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong
Aya El-Helali Department of Clinical Oncology, The University of Hong Kong, Hong Kong Island, Hong Kong
Tai-Chung Lam Department of Clinical Oncology, The University of Hong Kong, Hong Kong Island, Hong Kong
Fung-Ching Cheung Department of Neurosurgery, Queen Elizabeth Hospital, Kowloon, Hong Kong
Wai-Sang Poon Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong

Collapse

Lam WW, Chudzik A, Lehman N, Łazorczyk A, Kozioł P, Niedziałek A, Gananathan A, Orzyłowska A, Rola R, Stanisz GJ. Saturation transfer (CEST and MT) MRI for characterization of U-87 MG glioma in the rat. NMR IN BIOMEDICINE 2025;38:e5282. [PMID: 39473129 PMCID: PMC11631369 DOI: 10.1002/nbm.5282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 10/04/2024] [Accepted: 10/05/2024] [Indexed: 12/12/2024]

Abstract

The focus of this work was to identify the optimal magnetic resonance imaging (MRI) contrast between orthotopic U-87 MG tumours and normal appearing brain with the eventual goal of treatment response monitoring. U-87 MG human glioblastoma cells were injected into the brain of RNU nude rats (n = 9). The rats were imaged at 7 T at three timepoints for all animals: 3-5, 7-9, and 11-13 days after implantation. Whole-brain T1-weighted (before and after gadolinium contrast agent injection), diffusion, and fluid-attenuated inversion recovery scans were performed. In addition, single-slice saturation-transfer-weighted chemical exchange saturation transfer (CEST), magnetization transfer (MT), and water saturation shift referencing (WASSR) contrast Z-spectra and T1 and T2 maps were also acquired. The MT and WASSR Z-spectra and T1 map were fitted to a two-pool quantitative MT model to estimate the T2 of the free and macromolecular-bound water molecules, the relative macromolecular pool size (M0, MT), and the magnetization exchange rate from the macromolecular pool to the free pool (RMT). The T1-corrected apparent exchange-dependent relaxation (AREX) metric to isolate the CEST contributions was also calculated. The lesion on M0, MT and AREX maps with a B1 of 2 μT best matched the hyperintensity on the post-contrast T1-weighted image. There was also good separation in Z-spectra between the lesion and contralateral cortex in the 2-μT CEST and 3- and 5-μT MT Z-spectra at all time points. A pairwise Wilcoxon signed-rank tests with Holm-Bonferroni adjustment on MRI parameters was performed and the differences between enhancing lesion and contralateral cortex for the MT ratio with 2 μT saturation at 3.6 ppm frequency offset (corresponding to the amide chemical group) and M0, MT were both strongly significant (p < 0.001) at all time points. This work has identified that differences between enhancing lesion and contralateral cortex are strongest in MTR with B1 = 2 μT at 3.6 ppm and relative macromolecular pool size (M0, MT) images over entire period of 3-13 days after cancer cell implantation.

Collapse

Wang M, Graner AN, Knowles B, McRae C, Fringuello A, Paucek P, Gavrilovic M, Redwine M, Hanson C, Coughlan C, Grimaldo-Garcia S, Metzger B, Bolus V, Kopper TJ, Smith M, Zhou W, Lenz M, Abosch A, Ojemann S, Lillehei KO, Yu X, Graner MW. Differential Effects of Extracellular Vesicles from Two Different Glioblastomas on Normal Human Brain Cells. Neurol Int 2024;16:1355-1384. [PMID: 39585062 PMCID: PMC11587087 DOI: 10.3390/neurolint16060103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2024] [Revised: 10/23/2024] [Accepted: 11/01/2024] [Indexed: 11/26/2024] Open

Affiliation(s)

Mary Wang Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Arin N. Graner Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Bryne Knowles Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA
Charlotte McRae Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
Anthony Fringuello Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Department of Cell Biology, State University of New York Downstate Health Sciences University, New York, NY 11203, USA
Petr Paucek Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Michael Gavrilovic Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Department of Biomedical Sciences, Regis University, Denver, CO 80221, USA St Louis University School of Medicine, St. Louis, MO 63104, USA
McKenna Redwine Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Department of Biomedical Sciences, Regis University, Denver, CO 80221, USA
Caleb Hanson Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Department of Biomedical Sciences, Regis University, Denver, CO 80221, USA
Christina Coughlan Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA;
Stacey Grimaldo-Garcia Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Department of Neuroscience, Middlebury College, Middlebury, VT 05753, USA
Brooke Metzger Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Occupational Therapy, Illinois College, Jacksonville, IL 62650, USA Neuroscience, Midwestern University, Glendale, AZ 85308, USA
Vince Bolus Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
Timothy J. Kopper Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Marie Smith Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Wenbo Zhou Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Morgan Lenz Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.) Occupational Therapy, Illinois College, Jacksonville, IL 62650, USA
Aviva Abosch Department of Neurosurgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA;
Steven Ojemann Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Kevin O. Lillehei Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Xiaoli Yu Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)
Michael W. Graner Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; (M.W.); (A.N.G.); (B.K.); (C.M.); (A.F.); (P.P.); (M.G.); (M.R.); (C.H.); (S.G.-G.); (B.M.); (V.B.); (T.J.K.); (M.S.); (W.Z.); (M.L.); (S.O.); (K.O.L.); (X.Y.)

Collapse

da Silva EB, Ramina R, Novak Filho JL, Jung GS, Bornancin GX, Neto MC. Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations. J Neurooncol 2024;168:555-562. [PMID: 38709355 DOI: 10.1007/s11060-024-04698-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Accepted: 04/25/2024] [Indexed: 05/07/2024]

Köy Y, Ceylan O, Kahraman A, Cangi S, Özmen S, Tihan T. A retrospective analysis of practical benefits and caveats of the new WHO 2021 central nervous system tumor classification scheme in low-resource settings: "A perspective from low- and middle-income countries". Neuropathology 2024;44:183-189. [PMID: 38029519 DOI: 10.1111/neup.12953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 10/19/2023] [Accepted: 10/21/2023] [Indexed: 12/01/2023]

Zhu P, Pichardo-Rojas PS, Dono A, Tandon N, Hadjipanayis CG, Berger MS, Esquenazi Y. The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database. J Neurooncol 2024;168:77-89. [PMID: 38492191 DOI: 10.1007/s11060-024-04644-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Accepted: 03/12/2024] [Indexed: 03/18/2024]

Abstract

PURPOSE

Aggressive resection in surgically-accessible glioblastoma (GBM) correlates with improved survival over less extensive resections. However, the clinical impact of performing a biopsy before definitive resection have not been previously evaluated.

METHODS

We analyzed 17,334 GBM patients from the NCDB from 2010-2014. We categorized them into: "upfront resection" and "biopsy followed by resection". The outcomes of interes included OS, 30-day readmission/mortality, 90-day mortality, and length of hospital stay (LOS). The Kaplan-Meier methods and accelerated failure time (AFT) models were applied for survival analysis. Multivariable binary logistic regression were performed to compare differences among groups. Multiple imputation and propensity score matching (PSM) were conducted for validation.

RESULTS

"Upfront resection" had superior OS over "biopsy followed by resection" (median OS:12.4 versus 11.1 months, log-rank p = 0.001). Similarly, multivariable AFT models favored "upfront resection" (time ratio[TR]:0.83, 95%CI: 0.75-0.93, p = 0.001). Patients undergoing "upfront gross-total resection (GTR)" had higher OS over "upfront subtotal resection (STR)", "GTR following STR", and "GTR or STR following initial biopsy" (14.4 vs. 10.3, 13.5, 13.3, and 9.1 months;TR: 1.00 [Ref.], 0.75, 0.82, 0.88, and 0.67). Recent years of diagnosis, higher income, facilities located in Southern regions, and treatment at academic facilities were significantly associated with the higher likelihood of undergoing upfront resection. Multivariable regression showed a decreased 30 and 90-day mortality for patients undergoing "upfront resection", 73% and 44%, respectively (p < 0.001).

CONCLUSIONS

Pre-operative biopsies for surgically accessible GBM are associated with worse survival despite subsequent resection compared to patients undergoing upfront resection.

Collapse

Wang M, Graner AN, Knowles B, McRae C, Fringuello A, Paucek P, Gavrilovic M, Redwine M, Hanson C, Coughlan C, Metzger B, Bolus V, Kopper T, Smith M, Zhou W, Lenz M, Abosch A, Ojemann S, Lillehei KO, Yu X, Graner MW. A tale of two tumors: differential, but detrimental, effects of glioblastoma extracellular vesicles (EVs) on normal human brain cells. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.04.08.588622. [PMID: 38645117 PMCID: PMC11030303 DOI: 10.1101/2024.04.08.588622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]

Tanrikulu L, Seifart U. Neurooncological Rehabilitation in Diffuse Gliomas. Cureus 2024;16:e57534. [PMID: 38707095 PMCID: PMC11066719 DOI: 10.7759/cureus.57534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/03/2024] [Indexed: 05/07/2024] Open

Abstract

BACKGROUND

With the further advancement of surgical technology and modern tumor-targeted treatment strategies, longer survival rates can be achieved in diffuse gliomas. Pre- and post-therapeutic physical and cognitive deficits are frequently associated with gliomas. The clinical impact of physical therapy and rehabilitation on neurooncological disorders has not been analyzed consecutively. This study investigates the clinical effect of rehabilitation in patients with diffuse gliomas.

METHODS

Patients with surgically and radio-/oncologically treated diffuse gliomas were recruited into this study. They were admitted to an inpatient program for three weeks. The patients underwent physical and occupational therapy, exercise programs, and psychooncological support. The outcome measures included motor strength, mobility, neuropsychological deficits, and tumor localization-dependent symptoms for the statistical determination and comparison of the respective Eastern Cooperative Oncology Group (ECOG) scores on admission and discharge by a two-tailed t-test.

RESULTS

A total of 25 patients (f/m: 11/14) with diffuse gliomas were recruited into the program. Four patients (16%) had CNS WHO grade 2, seven patients (28%) had grade 3, and 14 patients (56%) had grade 4 tumors. Major improvement in motor, cognitive, and functions of the daily activities was achieved in the examined population. Major improvement in motor, cognitive, and neurological functions of the daily activities screened in the admission of all patients was achieved. The comparison of the ECOG scores determined on admission and on discharge showed a statistical significance derived from the undertaken t-test with a p-value <0.05.

CONCLUSION

We herein show that a clearly defined inpatient rehabilitation protocol significantly enables the improvement of the quality of life of patients with diffuse gliomas. The effectiveness of the exercise program and psychooncological assistance was confirmed by the course of patient-reported functions. Based on the limited number of our patient collective, multicenter studies with broader patient sizes should be performed to confirm our significant results.

Collapse

Pöhlmann J, Weller M, Marcellusi A, Grabe-Heyne K, Krott-Coi L, Rabar S, Pollock RF. High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma. Front Oncol 2024;14:1368606. [PMID: 38571509 PMCID: PMC10987841 DOI: 10.3389/fonc.2024.1368606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 02/28/2024] [Indexed: 04/05/2024] Open

Pichardo-Rojas PS, Zarate C, Arguelles-Hernández J, Barrón-Lomelí A, Sanchez-Velez R, Hjeala-Varas A, Gutierrez-Herrera E, Tandon N, Esquenazi Y. Intraoperative ultrasound for surgical resection of high-grade glioma and glioblastoma: a meta-analysis of 732 patients. Neurosurg Rev 2024;47:120. [PMID: 38498065 DOI: 10.1007/s10143-024-02354-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 01/05/2024] [Accepted: 03/13/2024] [Indexed: 03/19/2024]

Kosianova А, Pak O, Bryukhovetskiy I. Regulation of cancer stem cells and immunotherapy of glioblastoma (Review). Biomed Rep 2024;20:24. [PMID: 38170016 PMCID: PMC10758921 DOI: 10.3892/br.2023.1712] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 11/24/2023] [Indexed: 01/05/2024] Open

Poniatowski ŁA, Woźnica M, Wojdasiewicz P, Mela-Kalicka A, Romanowska-Próchnicka K, Purrahman D, Żurek G, Krawczyk M, Nameh Goshay Fard N, Furtak-Niczyporuk M, Jaroszyński J, Mahmoudian-Sani MR, Joniec-Maciejak I. The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme. Cells 2024;13:124. [PMID: 38247816 PMCID: PMC10814625 DOI: 10.3390/cells13020124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/24/2023] [Accepted: 01/02/2024] [Indexed: 01/23/2024] Open

Abstract

Glioblastoma multiforme (GBM) represents the most common and aggressive malignant form of brain tumour in adults and is characterized by an extremely poor prognosis with dismal survival rates. Currently, expanding concepts concerning the pathophysiology of GBM are inextricably linked with neuroinflammatory phenomena. On account of this fact, the identification of novel pathomechanisms targeting neuroinflammation seems to be crucial in terms of yielding successful individual therapeutic strategies. In recent years, the pleiotropic growth factor progranulin (PGRN) has attracted significant attention in the neuroscience and oncological community regarding its neuroimmunomodulatory and oncogenic functions. This review of the literature summarizes and updates contemporary knowledge about PGRN, its associated receptors and signalling pathway involvement in GBM pathogenesis, indicating possible cellular and molecular mechanisms with potential diagnostic, prognostic and therapeutic targets in order to yield successful individual therapeutic strategies. After a review of the literature, we found that there are possible PGRN-targeted therapeutic approaches for implementation in GBM treatment algorithms both in preclinical and future clinical studies. Furthermore, PGRN-targeted therapies exerted their highest efficacy in combination with other established chemotherapeutic agents, such as temozolomide. The results of the analysis suggested that the possible implementation of routine determinations of PGRN and its associated receptors in tumour tissue and biofluids could serve as a diagnostic and prognostic biomarker of GBM. Furthermore, promising preclinical applications of PGRN-related findings should be investigated in clinical studies in order to create new diagnostic and therapeutic algorithms for GBM treatment.

Collapse

Affiliation(s)

Łukasz A. Poniatowski Department of Neurosurgery, Dietrich-Bonhoeffer-Klinikum, Salvador-Allende-Straße 30, 17036 Neubrandenburg, Germany
Michał Woźnica Department of Spine Surgery, 7th Navy Hospital, Polanki 117, 80-305 Gdańsk, Poland;
Piotr Wojdasiewicz Department of Biophysics, Physiology and Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland (K.R.-P.)
Aneta Mela-Kalicka Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland
Katarzyna Romanowska-Próchnicka Department of Biophysics, Physiology and Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland (K.R.-P.) Department of Systemic Connective Tissue Diseases, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland
Daryush Purrahman Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; (D.P.)
Grzegorz Żurek Department of Biostructure, Wrocław University of Health and Sport Sciences, I. J. Paderewskiego 35, 51-612 Wrocław, Poland;
Maciej Krawczyk 2nd Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland
Najmeh Nameh Goshay Fard Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; (D.P.)
Marzena Furtak-Niczyporuk Department of Public Health, Faculty of Medicine, Medical University of Lublin, Chodźki 1, 20-093 Lublin, Poland
Janusz Jaroszyński Department of Administrative Proceedings, Faculty of Law and Administration, Maria Curie-Skłodowska University of Lublin, Marii Curie-Skłodowskiej 5, 20-031 Lublin, Poland
Mohammad-Reza Mahmoudian-Sani Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; (D.P.)
Ilona Joniec-Maciejak Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland

Collapse

Yan S, Liu S, Di Ieva A, Pagnucco M, Song Y. Meta-transfer Learning for Brain Tumor Segmentation: Within and Beyond Glioma. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2024;1462:221-230. [PMID: 39523268 DOI: 10.1007/978-3-031-64892-2_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2024]

Xiao N, Yang W, Wang J, Li J, Zhao R, Li M, Li C, Liu K, Li Y, Yin C, Chen Z, Li X, Jiang Y. Protein structuromics: A new method for protein structure-function crosstalk in glioma. Proteins 2024;92:24-36. [PMID: 37497743 DOI: 10.1002/prot.26555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Revised: 06/16/2023] [Accepted: 07/04/2023] [Indexed: 07/28/2023]

Sai Krishna AVS, Ramu A, Hariharan S, Sinha S, Donakonda S. Characterization of tumor microenvironment in glioblastoma multiforme identifies ITGB2 as a key immune and stromal related regulator in glial cell types. Comput Biol Med 2023;165:107433. [PMID: 37660569 DOI: 10.1016/j.compbiomed.2023.107433] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 07/06/2023] [Accepted: 08/28/2023] [Indexed: 09/05/2023]

Zhou T, Zhu S. Uncertainty quantification and attention-aware fusion guided multi-modal MR brain tumor segmentation. Comput Biol Med 2023;163:107142. [PMID: 37331100 DOI: 10.1016/j.compbiomed.2023.107142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 05/17/2023] [Accepted: 06/05/2023] [Indexed: 06/20/2023]

Hoffman SE, Gupta S, O'Connor M, Jarvis CA, Zhao M, Hauser BM, Bernstock JD, Murphy S, Raftery SM, Lane K, Chiocca EA, Arnaout O. Reduced time to imaging, length of stay, and hospital charges following implementation of a novel postoperative pathway for craniotomy. J Neurosurg 2023;139:373-384. [PMID: 36609368 PMCID: PMC10904334 DOI: 10.3171/2022.12.jns222123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 12/05/2022] [Indexed: 01/09/2023]

Abstract

OBJECTIVE

The authors created a postoperative postanesthesia care unit (PACU) pathway to bypass routine intensive care unit (ICU) admissions of patients undergoing routine craniotomies, to improve ICU resource utilization and reduce overall hospital costs and lengths of stay while maintaining quality of care and patient satisfaction. In the present study, the authors evaluated this novel PACU-to-floor clinical pathway for a subset of patients undergoing craniotomy with a case time under 5 hours and blood loss under 500 ml.

METHODS

A single-institution retrospective cohort study was performed to compare 202 patients enrolled in the PACU-to-floor pathway and 193 historical controls who would have met pathway inclusion criteria. The pathway cohort consisted of all adult supratentorial brain tumor cases from the second half of January 2021 to the end of January 2022 that met the study inclusion criteria. Control cases were selected from the beginning of January 2020 to halfway through January 2021. The authors also discuss common themes of similar previously published pathways and the logistical and clinical barriers overcome for successful PACU pathway implementation.

RESULTS

Pathway enrollees had a median age of 61 years (IQR 49-69 years) and 53% were female. Age, sex, pathology, and American Society of Anesthesiologists physical status distributions were similar between pathway and control patients (p > 0.05). Most of the pathway cases (96%) were performed on weekdays, and 31% had start times before noon. Nineteen percent of pathway patients had 30-day readmissions, most frequently for headache (16%) and syncope (10%), whereas 18% of control patients had 30-day readmissions (p = 0.897). The average time to MRI was 6 hours faster for pathway patients (p < 0.001) and the time to inpatient physical therapy and/or occupational therapy evaluation was 4.1 hours faster (p = 0.046). The average total length of stay was 0.7 days shorter for pathway patients (p = 0.02). A home discharge occurred in 86% of pathway cases compared to 81% of controls (p = 0.225). The average total hospitalization charges were $13,448 lower for pathway patients, representing a 7.4% decrease (p = 0.0012, adjusted model). Seven pathway cases were escalated to the ICU postoperatively because of attending physician preference (2 cases), agitation (1 case), and new postoperative neurological deficits (4 cases), resulting in a 96.5% rate of successful discharge from the pathway. In bypassing the ICU, critical care resource utilization was improved by releasing 0.95 ICU days per patient, or 185 ICU days across the cohort.

CONCLUSIONS

The featured PACU-to-floor pathway reduces the stay of postoperative craniotomy patients and does not increase the risk of early hospital readmission.

Collapse

Zhou T, Ruan S, Hu H. A literature survey of MR-based brain tumor segmentation with missing modalities. Comput Med Imaging Graph 2023;104:102167. [PMID: 36584536 DOI: 10.1016/j.compmedimag.2022.102167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 11/01/2022] [Accepted: 12/22/2022] [Indexed: 12/28/2022]

Mowforth OD, Brannigan J, El Khoury M, Sarathi CIP, Bestwick H, Bhatti F, Mair R. Personalised therapeutic approaches to glioblastoma: A systematic review. Front Med (Lausanne) 2023;10:1166104. [PMID: 37122327 PMCID: PMC10140534 DOI: 10.3389/fmed.2023.1166104] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 03/23/2023] [Indexed: 05/02/2023] Open

Abstract

Introduction

Glioblastoma is the most common and malignant primary brain tumour with median survival of 14.6 months. Personalised medicine aims to improve survival by targeting individualised patient characteristics. However, a major limitation has been application of targeted therapies in a non-personalised manner without biomarker enrichment. This has risked therapies being discounted without fair and rigorous evaluation. The objective was therefore to synthesise the current evidence on survival efficacy of personalised therapies in glioblastoma.

Methods

Studies reporting a survival outcome in human adults with supratentorial glioblastoma were eligible. PRISMA guidelines were followed. MEDLINE, Embase, Scopus, Web of Science and the Cochrane Library were searched to 5th May 2022. Clinicaltrials.gov was searched to 25th May 2022. Reference lists were hand-searched. Duplicate title/abstract screening, data extraction and risk of bias assessments were conducted. A quantitative synthesis is presented.

Results

A total of 102 trials were included: 16 were randomised and 41 studied newly diagnosed patients. Of 5,527 included patients, 59.4% were male and mean age was 53.7 years. More than 20 types of personalised therapy were included: targeted molecular therapies were the most studied (33.3%, 34/102), followed by autologous dendritic cell vaccines (32.4%, 33/102) and autologous tumour vaccines (10.8%, 11/102). There was no consistent evidence for survival efficacy of any personalised therapy.

Conclusion

Personalised glioblastoma therapies remain of unproven survival benefit. Evidence is inconsistent with high risk of bias. Nonetheless, encouraging results in some trials provide reason for optimism. Future focus should address target-enriched trials, combination therapies, longitudinal biomarker monitoring and standardised reporting.

Collapse

Paiva ALC, Vitorino-Araujo JL, Lovato RM, Costa GHFD, Veiga JCE. An economic study of neuro-oncological patients in a large developing country: a cost analysis. ARQUIVOS DE NEURO-PSIQUIATRIA 2022;80:1149-1158. [PMID: 36577414 PMCID: PMC9797276 DOI: 10.1055/s-0042-1758649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]

Cost Matrix of Molecular Pathology in Glioma-Towards AI-Driven Rational Molecular Testing and Precision Care for the Future. Biomedicines 2022;10:biomedicines10123029. [PMID: 36551786 PMCID: PMC9775648 DOI: 10.3390/biomedicines10123029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 11/09/2022] [Accepted: 11/19/2022] [Indexed: 11/27/2022] Open

Jia J, Han Z, Wang X, Zheng X, Wang S, Cui Y. H2B gene family: A prognostic biomarker and correlates with immune infiltration in glioma. Front Oncol 2022;12:966817. [PMID: 36387186 PMCID: PMC9641242 DOI: 10.3389/fonc.2022.966817] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Accepted: 09/28/2022] [Indexed: 11/02/2023] Open

Das S, Nayak GK, Saba L, Kalra M, Suri JS, Saxena S. An artificial intelligence framework and its bias for brain tumor segmentation: A narrative review. Comput Biol Med 2022;143:105273. [PMID: 35228172 DOI: 10.1016/j.compbiomed.2022.105273] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2021] [Revised: 01/15/2022] [Accepted: 01/24/2022] [Indexed: 02/06/2023]

Abstract

BACKGROUND

Artificial intelligence (AI) has become a prominent technique for medical diagnosis and represents an essential role in detecting brain tumors. Although AI-based models are widely used in brain lesion segmentation (BLS), understanding their effectiveness is challenging due to their complexity and diversity. Several reviews on brain tumor segmentation are available, but none of them describe a link between the threats due to risk-of-bias (RoB) in AI and its architectures. In our review, we focused on linking RoB and different AI-based architectural Cluster in popular DL framework. Further, due to variance in these designs and input data types in medical imaging, it is necessary to present a narrative review considering all facets of BLS.

APPROACH

The proposed study uses a PRISMA strategy based on 75 relevant studies found by searching PubMed, Scopus, and Google Scholar. Based on the architectural evolution, DL studies were subsequently categorized into four classes: convolutional neural network (CNN)-based, encoder-decoder (ED)-based, transfer learning (TL)-based, and hybrid DL (HDL)-based architectures. These studies were then analyzed considering 32 AI attributes, with clusters including AI architecture, imaging modalities, hyper-parameters, performance evaluation metrics, and clinical evaluation. Then, after these studies were scored for all attributes, a composite score was computed, normalized, and ranked. Thereafter, a bias cutoff (AP(ai)Bias 1.0, AtheroPoint, Roseville, CA, USA) was established to detect low-, moderate- and high-bias studies.

CONCLUSION

The four classes of architectures, from best-to worst-performing, are TL > ED > CNN > HDL. ED-based models had the lowest AI bias for BLS. This study presents a set of three primary and six secondary recommendations for lowering the RoB.

Collapse

Morris K, Nami M, Bolanos JF, Lobo MA, Sadri-Naini M, Fiallos J, Sanchez GE, Bustos T, Chintam N, Amaya M, Strand SE, Mayuku-Dore A, Sakibova I, Biso GMN, DeFilippis A, Bravo D, Tarhan N, Claussen C, Mercado A, Braun S, Yuge L, Okabe S, Taghizadeh-Hesary F, Kotliar K, Sadowsky C, Chandra PS, Tripathi M, Katsaros V, Mehling B, Noroozian M, Abbasioun K, Amirjamshidi A, Hossein-Zadeh GA, Naraghi F, Barzegar M, Asadi-Pooya AA, Sahab-Negah S, Sadeghian S, Fahnestock M, Dilbaz N, Hussain N, Mari Z, Thatcher RW, Sipple D, Sidhu K, Chopra D, Costa F, Spena G, Berger T, Zelinsky D, Wheeler CJ, Ashford JW, Schulte R, Nezami MA, Kloor H, Filler A, Eliashiv DS, Sinha D, DeSalles AAF, Sadanand V, Suchkov S, Green K, Metin B, Hariri R, Cormier J, Yamamoto V, Kateb B. Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies. J Alzheimers Dis 2021;83:1563-1601. [PMID: 34487051 DOI: 10.3233/jad-215190] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]

Affiliation(s)

Kevin Morris Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Mohammad Nami Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Iran.,Middle East Brain + Initiative, Los Angeles, CA, USA.,Neuroscience Center, Instituto de Investigaciones Científicas Servicios de Alta Tecnología, City of Knowledge, Panama City, Panama
Joe F Bolanos Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Maria A Lobo Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Melody Sadri-Naini Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
John Fiallos Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Gilberto E Sanchez Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Teshia Bustos Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Nikita Chintam Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Marco Amaya Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Susanne E Strand Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Alero Mayuku-Dore Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Indira Sakibova Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Grace Maria Nicole Biso Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Alejandro DeFilippis Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Daniela Bravo Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Nevzat Tarhan Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Middle East Brain + Initiative, Los Angeles, CA, USA.,Department of Psychiatry, Faculty of Medicine, Uskudar University, Istanbul, Turkey
Carsten Claussen Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Fraunhofer-Institute for Translational Research and Pharmacology, Hamburg, Germany
Alejandro Mercado Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Department of Neurosurgery, Hospital Military Regional Mendoza, Mendoza, Argentina
Serge Braun AFM-Telethon France, Paris, France
Louis Yuge Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Division of Bio-Environment Adaptation Sciences, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.,Cell Therapy Venture Company, Space Bio-Laboratories, Hiroshima, Japan
Shigeo Okabe Brain Medical Science Collaboration Division, RIKEN Center for Brain Science Institution and Department: Cellular Neurobiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Farhad Taghizadeh-Hesary Social Science Research Institute, Tokai University, Shibuya City, Tokyo, Japan
Konstantin Kotliar Department of Biomedical Engineering, Aachen University of Applied Sciences, Aachen, Germany
Christina Sadowsky International Center for Spinal Cord Injury, Kennedy Krieger Institute-Johns Hopkins School of Medicine, Baltimore, MD, USA
P Sarat Chandra Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
Manjari Tripathi Department of Neurology, AIIMS, New Delhi, India
Vasileios Katsaros Department of Advanced Imaging Modalities, MRI Unit, General Anti-Cancer and Oncological Hospital of Athens "St. Savvas", Athens, Greece.,Departments of Neurosurgery and Neurology, National and Kapodistrian University of Athens, Athens, Greece.,Department of Neuroradiology, University College of London, London, UK
Brian Mehling T-Neuro Pharma, Inc., Albuquerque, NM, USA.,StemVax LLC, Chesterland, OH, USA
Maryam Noroozian Middle East Brain + Initiative, Los Angeles, CA, USA.,Cognitive Neurology and Neuropsychiatry Division, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
Kazem Abbasioun Middle East Brain + Initiative, Los Angeles, CA, USA.,Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran
Abbas Amirjamshidi Middle East Brain + Initiative, Los Angeles, CA, USA.,Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran
Gholam-Ali Hossein-Zadeh Middle East Brain + Initiative, Los Angeles, CA, USA.,National Brain Mapping Laboratory, Tehran, Iran
Faridedin Naraghi Middle East Brain + Initiative, Los Angeles, CA, USA.,Iranian Society for Brain Mapping & Therapeutics, Tehran, Iran
Mojtaba Barzegar Middle East Brain + Initiative, Los Angeles, CA, USA.,Intelligent Quantitative Bio-Medical Imaging, Tehran, Iran, and Medical Physics Department, Tehran University of Medical Sciences, Tehran, Iran
Ali A Asadi-Pooya Middle East Brain + Initiative, Los Angeles, CA, USA.,Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.,Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA
Sajad Sahab-Negah Middle East Brain + Initiative, Los Angeles, CA, USA.,Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad Iran.,Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran
Saeid Sadeghian Middle East Brain + Initiative, Los Angeles, CA, USA.,Department of Pediatric Neurology, Golestan Medical, Educational, and Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Margaret Fahnestock Lafayette Surgical Specialty Hospital, Lafayette, LA, USA
Nesrin Dilbaz Department of Psychiatry, Faculty of Medicine, Uskudar University, Istanbul, Turkey
Namath Hussain Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Loma Linda University, School of Medicine, Loma Linda, CA, USA
Zoltan Mari Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
Robert W Thatcher Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Applied Neuroscience Research Institute, St. Petersburg, FL, USA.,Applied Neuroscience, Inc., St. Petersburg, Fl, USA
Daniel Sipple Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA.,Fraunhofer-Institute for Translational Research and Pharmacology, Hamburg, Germany
Kuldip Sidhu Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA.,CK Cell Technologies Pty Ltd, Norwest, NSW, Australia.,Faculty of Medicine, Centre for Healthy Brain Ageing, University of New South Wales, Sydney, NSW, Australia.,Society for Brain Mapping and Therapeutics-Sydney, Sydney, NSW, Australia
Deepak Chopra The Chopra Foundation, Orlando, FL, USA
Francesco Costa IRCCS Humanitas Research Hospital, Milan, Italy.,Department of Biomedical Sciences, Humanitas University, Milan, Italy
Giannantonio Spena Azienda Ospedaliera della Provincia di Lecco, Brescia, Italy
Ted Berger Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,USC Department of Biomedical Engineering, Los Angeles, CA, USA
Deborah Zelinsky Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,The Mind-Eye Institute, Northbrook, IL, USA
Christopher J Wheeler Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Social Science Research Institute, Tokai University, Shibuya City, Tokyo, Japan
J Wesson Ashford Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
Reinhard Schulte Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Loma Linda University, School of Medicine, Loma Linda, CA, USA
M A Nezami Sahel Oncology LLC, Newport Beach, CA, USA
Harry Kloor Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Beyond Imagination, Los Angeles, CA, USA
Aaron Filler Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA.,Institute for Nerve Medicine, Santa Monica, CA, USA
Dawn S Eliashiv Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Department of Neurology, UCLA-David Geffen School of Medicine, Los Angeles, CA, USA
Dipen Sinha Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA
Antonio A F DeSalles Department of Neurosurgery, UCLA David Geffen School of Medicine, Los Angeles CA, USA.,NeuroSapiens - Rede D'Or São Luiz, Sao Paulo, Brazil.,Society for Brain Mapping and Therapeutics-Brazil, Sao Paulo, Brazil
Venkatraman Sadanand Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Sergey Suchkov Applied Neuroscience, Inc., St. Petersburg, Fl, USA.,Society for Brain Mapping and Therapeutics-Russia, Moscow, Russia
Ken Green Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA
Barish Metin Middle East Brain + Initiative, Los Angeles, CA, USA.,Department of Psychiatry, Faculty of Medicine, Uskudar University, Istanbul, Turkey
Robert Hariri Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA.,Celularity Corporation, Warren, NJ, USA.,Weill Cornell School of Medicine, Department of Neurosurgery, New York, NY, USA
Jason Cormier Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Blue Horizon International, Hackensack, NJ, USA
Vicky Yamamoto Society for Brain Mapping and Therapeutics, Los Angeles, CA, USA.,Brain Mapping Foundation, Los Angeles, CA, USA.,USC Keck School of Medicine, The USC Caruso Department of Otolaryngology-Head and Neck Surgery, Los Angeles, CA, USA.,USC-Norris Comprehensive Cancer Center, Los Angeles, CA, USA
Babak Kateb Middle East Brain + Initiative, Los Angeles, CA, USA.,Loma Linda University, School of Medicine, Loma Linda, CA, USA.,National Center for Nanobioelectronics, Los Angeles, CA, USA.,Brain Technology and Innovation Park, Los Angeles, CA, USA

Collapse